Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010938 | 0.80 | LTA4H (0.33) | — | |
| SCHEMBL1012105 | 0.80 | HRH3 (0.40) | ALDH1A1HRH3KDM4EPOLB | |
| SCHEMBL1011864 | 0.80 | MAPT (0.47) | MAPTALDH1A1MAPK1LMNAHTT | |
| SCHEMBL1012009 | 0.79 | MAPT (0.44) | MAPTALDH1A1MAPK1LMNAHTT | |
| SCHEMBL1012040 | 0.76 | KDM4E (0.40) | MAPTALDH1A1MAPK1HTTGFER | |
| SCHEMBL1010053 | 0.76 | DRD4 (0.40) | MAPTALDH1A1MAPK1LMNAHTT | |
| SCHEMBL11530804 | 0.74 | MAPT (0.46) | MAPTALDH1A1MAPK1LMNAHTT | |
| SCHEMBL11527859 | 0.74 | MAPT (0.42) | MAPTALDH1A1MAPK1LMNAHTT | |
| SCHEMBL1012345 | 0.72 | NQO1 (0.45) | MAPTALDH1A1MAPK1LMNAHTT | |
| SCHEMBL1010081 | 0.72 | ADRB1 (0.43) | MAPTALDH1A1LMNAKDM4ENOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372844-B1 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INST OF TECHN (US) | 2011-01-05 | — | — | EP | claimed |
| US-6838489-B2 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | CYMETECH, LLC (US) | 2005-01-04 | — | — | US | claimed |
| US-20030144437-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | STERLING JA, L.C. | 2003-07-31 | — | — | US | claimed |
| US-20030083445-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | STERLING JA, L.C. | 2003-05-01 | — | — | US | claimed |
| US-20120241250-A1 | Aerial Work Platforms and Aerial Work Platform Assemblies Comprised of Polymerized Cycloolefin Monomers | EAKIN GEORGE R (US) | 2012-09-27 | — | — | US | disclosed |
| EP-1372844-B1 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INST OF TECHN (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-1372844-A4 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INST OF TECHN (US) | 2005-10-12 | — | — | EP | disclosed |
| US-6838489-B2 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | CYMETECH, LLC (US) | 2005-01-04 | — | — | US | disclosed |
| EP-1372844-A1 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | California Institute of Technology (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003097562-A2 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030144437-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | STERLING JA, L.C. | 2003-07-31 | — | — | US | disclosed |
| US-20030083445-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | STERLING JA, L.C. | 2003-05-01 | — | — | US | disclosed |
| WO-2002076613-A1 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2002-10-03 | — | — | WO | disclosed |
| US-4161528-A | INSECTICIDES; MITICIDES | CELAMERCK GMBH & CO. KG. (DE) | 1979-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144437-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | NQO1, NIT2, ALOX5 | MAPT 4167/4885ALDH1A1 1236/4885MAPK1 2366/4885 |
| US-20030083445-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | NQO1, NIT2, ALOX5 | MAPT 4167/4885ALDH1A1 1236/4885MAPK1 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.